[{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Doxorubicin Hydrochloride","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medicus Pharma \/ Maxim Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Maxim Group LLC"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Doxorubicin Hydrochloride","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medicus Pharma \/ Maxim Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Maxim Group LLC"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Swanielle Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Collaboration","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medicus Pharma \/ Swanielle Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Swanielle Inc"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Patch","sponsorNew":"Medicus Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Patch","sponsorNew":"Medicus Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Patch","sponsorNew":"Medicus Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Medicus Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : D-MNA (doxorubicin) is a dissolvable transdermal patch featuring cellulose-based microneedle arrays loaded with doxorubicin. It is being evaluated for the treatment of nodular basal cell carcinoma.

                          Product Name : D-MNA

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          March 06, 2025

                          Lead Product(s) : Doxorubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : D-MNA (doxorubicin) is a dissolvable transdermal patch featuring cellulose-based microneedle arrays loaded with doxorubicin. It is being evaluated for the treatment of nodular basal cell carcinoma.

                          Product Name : D-MNA

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          February 27, 2025

                          Lead Product(s) : Doxorubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : D-MNA (doxorubicin) is a dissolvable transdermal patch featuring cellulose-based microneedle arrays loaded with doxorubicin. It is being evaluated for the treatment of nodular basal cell carcinoma.

                          Product Name : D-MNA

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          February 14, 2025

                          Lead Product(s) : Doxorubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : The collaboration aims to explore expansion of Phase 2 clinical study evaluating D-MNA, microneedle arrays containing doxorubicin for treatment of Basal Cell Carcinoma in the Asia-pacific region.

                          Product Name : D-MNA

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Undisclosed

                          December 02, 2024

                          Lead Product(s) : Doxorubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Swanielle Inc

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : The Company intends to use the proceeds to fund its Phase 2 proof of concept trial for basal cell carcinoma using its doxorubicin tip loaded dissolvable microarray needle skinpatch, D-MNA.

                          Product Name : D-MNA

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 19, 2024

                          Lead Product(s) : Doxorubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Maxim Group LLC

                          Deal Size : $4.0 million

                          Deal Type : Public Offering

                          blank

                          06

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : The Company intends to use the proceeds to fund its Phase 2 proof of concept trial for basal cell carcinoma using its doxorubicin tip loaded dissolvable microarray needle skinpatch, D-MNA.

                          Product Name : D-MNA

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 13, 2024

                          Lead Product(s) : Doxorubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Maxim Group LLC

                          Deal Size : $4.0 million

                          Deal Type : Public Offering

                          blank